Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.

Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, Diaz R, Alings M, Lonn EM, Anand SS, Widimsky P, Hori M, Avezum A, Piegas LS, Branch KRH, Probstfield J, Bhatt DL, Zhu J, Liang Y, Maggioni AP, Lopez-Jaramillo P, O'Donnell M, Kakkar AK, Fox KAA, Parkhomenko AN, Ertl G, Störk S, Keltai M, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Verhamme PB, Vinereanu D, Kim JH, Tonkin AM, Lewis BS, Felix C, Yusoff K, Steg PG, Metsarinne KP, Cook Bruns N, Misselwitz F, Chen E, Leong D, Yusuf S; COMPASS Investigators.

N Engl J Med. 2017 Oct 5;377(14):1319-1330. doi: 10.1056/NEJMoa1709118. Epub 2017 Aug 27.

PMID:
28844192
2.

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.

Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, Lawson FC, Ping L, Wei X, Lewis EF, Maggioni AP, McMurray JJ, Probstfield JL, Riddle MC, Solomon SD, Tardif JC; ELIXA Investigators.

N Engl J Med. 2015 Dec 3;373(23):2247-57. doi: 10.1056/NEJMoa1509225.

3.

Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo.

Bentley-Lewis R, Aguilar D, Riddle MC, Claggett B, Diaz R, Dickstein K, Gerstein HC, Johnston P, Køber LV, Lawson F, Lewis EF, Maggioni AP, McMurray JJ, Ping L, Probstfield JL, Solomon SD, Tardif JC, Wu Y, Pfeffer MA; ELIXA Investigators.

Am Heart J. 2015 May;169(5):631-638.e7. doi: 10.1016/j.ahj.2015.02.002. Epub 2015 Feb 12.

PMID:
25965710
4.

New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2).

Yki-Järvinen H, Bergenstal R, Ziemen M, Wardecki M, Muehlen-Bartmer I, Boelle E, Riddle MC; EDITION 2 Study Investigators.

Diabetes Care. 2014 Dec;37(12):3235-43. doi: 10.2337/dc14-0990. Epub 2014 Sep 5.

PMID:
25193531
5.

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I; SAVOR-TIMI 53 Steering Committee and Investigators.

N Engl J Med. 2013 Oct 3;369(14):1317-26. doi: 10.1056/NEJMoa1307684. Epub 2013 Sep 2.

6.

Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes.

DREAM On (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication Ongoing Follow-up) Investigators, Gerstein HC, Mohan V, Avezum A, Bergenstal RM, Chiasson JL, Garrido M, MacKinnon I, Rao PV, Zinman B, Jung H, Joldersma L, Bosch J, Yusuf S.

Diabetologia. 2011 Mar;54(3):487-95. doi: 10.1007/s00125-010-1985-4. Epub 2010 Nov 30.

PMID:
21116607
7.

Anti-Mullerian hormone and inhibin B levels as markers of premature ovarian aging and transition to menopause in type 1 diabetes mellitus.

Soto N, Iñiguez G, López P, Larenas G, Mujica V, Rey RA, Codner E.

Hum Reprod. 2009 Nov;24(11):2838-44. doi: 10.1093/humrep/dep276. Epub 2009 Jul 30.

PMID:
19643804
8.

Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.

DREAM Trial Investigators, Dagenais GR, Gerstein HC, Holman R, Budaj A, Escalante A, Hedner T, Keltai M, Lonn E, McFarlane S, McQueen M, Teo K, Sheridan P, Bosch J, Pogue J, Yusuf S.

Diabetes Care. 2008 May;31(5):1007-14. doi: 10.2337/dc07-1868. Epub 2008 Feb 11.

PMID:
18268075
9.

Voltammetric behavior of zaleplon and its differential pulse polarographic determination in capsules.

Larenas G, Bollo S, Rodriguez M, Lemus I, Nuñez-Vergara LJ, Squella JA, Alvarez-Lueje A.

J AOAC Int. 2005 Jul-Aug;88(4):1135-41.

PMID:
16152932
10.

[Prevalence of type 2 diabetes and obesity in two Chilean aboriginal populations living in urban zones].

Carrasco EP, Pérez FB, Angel BB, Albala CB, Santos JL, Larenas GY, Montalvo DV.

Rev Med Chil. 2004 Oct;132(10):1189-97. Spanish.

PMID:
15631206
11.

[High prevalence of osteoporosis in asymptomatic postmenopausal Mapuche women].

Ponce L, Larenas G, Riedemann P.

Rev Med Chil. 2002 Dec;130(12):1365-72. Spanish.

PMID:
12611237
12.

[Seeds germination of Caesalpinia paraguariensis (Fabaceae): scarificator agents and cattle effects].

Ortega Baes P, de Viana ML, Larenas G, Saravia M.

Rev Biol Trop. 2001 Mar;49(1):301-4. Spanish.

PMID:
11795158
13.

Prevalence of type 2 diabetes and obesity in rural Mapuche population from Chile.

Pérez-Bravo F, Carrasco E, Santos JL, Calvillán M, Larenas G, Albala C.

Nutrition. 2001 Mar;17(3):236-8.

PMID:
11312066
14.

[Serum lipids and blood pressure levels in the +Mapuche population living in the Chilean region of Araucanía].

Stockins B, Larenas G, Charles M, Standen D, Espinoza O, Illesca M, Opazo JA, Carrasco B, Lanas F, Davis M.

Rev Med Chil. 1998 Nov;126(11):1291-9. Spanish.

PMID:
10349171
15.

[Clinical experience with an alpha glucosidase inhibitor (acarbose) in the treatment of non-insulin-dependent diabetes. Multicenter study].

García de los Ríos M, Mujica V, Muñoz S, Durruty P, Larenas G, López MI, Kuzmanic A, Pérez J, Flaskamp R, Cumsille F.

Rev Med Chil. 1997 Aug;125(8):856-62. Spanish.

PMID:
9580485
16.

Incidence of insulin-dependent diabetes mellitus in the IX region of Chile: ethnic differences.

Larenas G, Montecinos A, Manosalva M, Barthou M, Vidal T.

Diabetes Res Clin Pract. 1996 Oct;34 Suppl:S147-51.

PMID:
9015684
17.

[Chemical, sensory and clinical characterization of lupin marmalades].

Villarroel M, Biolley E, Larenas G, Wittig E, Díaz V, Muñoz Y.

Arch Latinoam Nutr. 1996 Sep;46(3):234-7. Spanish.

PMID:
9429628
18.

[Genetic predisposition to develop insulin-dependent diabetes mellitus. A population study in Santiago and Temuco, Chile].

Pérez F, Carrasco E, Calvillán M, Gutiérrez MD, Larenas G, López G, García de los Ríos M, Serrano M.

Rev Med Chil. 1995 Oct;123(10):1205-13. Spanish.

PMID:
8733311
19.

[Primary hyperparathyroidism caused by a mediastinal adenoma with intermittent hypercalcemia and severe bone disease].

Araya AV, Pumarino H, Larenas G, Gac A.

Rev Med Chil. 1992 May;120(5):563-70. Spanish.

PMID:
1343071
20.

[Prevalence of diabetes mellitus in a Mapuche community of Region IX, Chile].

Larenas G, Arias G, Espinoza O, Charles M, Landaeta O, Villanueva S, Espinoza A.

Rev Med Chil. 1985 Nov;113(11):1121-5. Spanish. No abstract available.

PMID:
3837299

Supplemental Content

Loading ...
Support Center